Document Detail

Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension.
MedLine Citation:
PMID:  2475687     Owner:  NLM     Status:  MEDLINE    
The efficacy of verapamil, a calcium channel blocker in slow-release form, 240 mg once a day, was assessed in 1,412 ambulatory, mildly to moderately hypertensive patients. Blood pressure decreased from 171.82 +/- 17/103.55 +/- 6 mm Hg at week 0 to 157 +/- 15/93.6 +/- 8 mm Hg at 2 weeks (p less than 0.001) in 78% of patients. At week 12 there were 1,249 patients (88%) controlled with therapy, either with verapamil alone (950 patients, 67%) or plus additional diuretic (21%). Blood pressure showed a mean decrease of 24.6 mm Hg in systolic and 17.2 mm Hg in diastolic pressure at week 12. Heart rate decreased from 81.4 +/- 11 beats/min at week 0 to 75.69 +/- 8.5 beats/min at week 12 (p less than 0.05). There were no statistical differences in the effect on diastolic blood pressure between elderly (greater than 65 years) and nonelderly patients in the study, although the elderly showed higher baseline systolic pressure (178.27 +/- 17 mm Hg vs. 168.97 +/- 16 mm Hg, p less than 0.001) than did nonelderly patients. Verapamil therapy produced a similar effect on systolic pressure (p = NS) in younger patients (23.96 mm Hg decrement) and in the elderly (25.93 mm Hg decrement). The overall incidence of adverse reactions was 16.58%, accounting for 1.06% of patients' withdrawals. Constipation (5%) was the most common side effect. We conclude that slow-release verapamil, 240 mg once a day, is an effective therapeutic alternative in systemic hypertension, and must be included in the first step of antihypertensive therapy.
C Gómez Pajuelo; J Pérez Naranjo; I Ruiz Martínez
Related Documents :
3826077 - Occupational exposure to lead and blood pressure: a study in 105 workers.
6378437 - Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypert...
7484887 - Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular ...
2090337 - Topical 2.5% and 5% phenylephrine: comparison of effects on heart rate and blood pressure.
7679457 - Role of no on pressure-natriuresis in wistar-kyoto and spontaneously hypertensive rats.
7890007 - Sacral root stimulation for controlled defecation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  13 Suppl 4     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1989  
Date Detail:
Created Date:  1989-09-22     Completed Date:  1989-09-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S50-2     Citation Subset:  IM    
Servicio de Cardiología, Hospital 1 de Octubre, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aging / physiology
Blood Pressure / drug effects
Delayed-Action Preparations
Heart Rate / drug effects
Hypertension / drug therapy*,  physiopathology
Middle Aged
Sex Factors
Verapamil / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Delayed-Action Preparations; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phas...
Next Document:  Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic pati...